Buchumschlag

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Kuan‐Ju Lin, Cheng‐Hsien Hung, James Cheng‐Chung Wei
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
von: Cheng‐Hsien Hung, et al.
Veröffentlicht: (2025)

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006–2021
von: Mehdi Osooli, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
von: Matthias Kelm, et al.
Veröffentlicht: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
von: Dingsheng Liu, et al.
Veröffentlicht: (2025)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
von: Maryam Irshad, et al.
Veröffentlicht: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
von: Jiacheng Li
Veröffentlicht: (2026)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
von: Nathan Grellier, et al.
Veröffentlicht: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
von: Kuo‐Cheng Wu, et al.
Veröffentlicht: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
von: Jeffrey D. McCurdy, et al.
Veröffentlicht: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Editorial: Upadacitinib in Perianal Crohn's Disease
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
von: Emmanuel Pio Pastore
Veröffentlicht: (2025)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
von: Weilun Gao, et al.
Veröffentlicht: (2024)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
von: Abhirup Chatterjee, et al.
Veröffentlicht: (2024)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Antoine Meyer, et al.
Veröffentlicht: (2025)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
von: Lynna Chen, et al.
Veröffentlicht: (2025)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
von: Péter Bacsur, et al.
Veröffentlicht: (2024)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
von: Xingfei Pan, et al.
Veröffentlicht: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
von: Vincenzo Stranges, et al.
Veröffentlicht: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
von: Runqi Wang, et al.
Veröffentlicht: (2026)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
von: Tim Eglinton
Veröffentlicht: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
von: Shlomi Cohen, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
von: C. Ramos‐Belinchon, et al.
Veröffentlicht: (2025)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
von: Maryam Alahmad, et al.
Veröffentlicht: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2025)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
von: Marco Mendolaro, et al.
Veröffentlicht: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2024)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
von: Nicolas Richard, et al.
Veröffentlicht: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
von: Nicolas Richard, et al.
Veröffentlicht: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
von: Chang Liu, et al.
Veröffentlicht: (2026)

The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)